Chairman Offers to Buy Shares, Invests $250K in Subsidiary R&D Amidst Financial Challenges

summarizeSummary

CytoMed Therapeutics' Chairman, Mr. Choo Chee Kong, is demonstrating strong personal conviction by offering to purchase up to 200,000 shares and investing $250,000 into a subsidiary for R&D, providing critical support amidst the company's financial challenges.

check_boxKey Events · Financing and Capital Events · GDTC

• Chairman's Share Purchase Offer

  Chairman and Director Mr. Choo Chee Kong offered to acquire up to 200,000 shares via private transactions, with a minimum acquisition of 100,000 shares. This follows his stated intent to increase his shareholding.

• Subsidiary R&D Investment

  Mr. Choo, through EP Capital Inc., invested approximately $250,000 into LongevityBank Pte Ltd, a subsidiary. This investment will fund the establishment of a new research and development laboratory.

• Increased Subsidiary Stake

  The investment increased EP Capital Inc.'s shareholding in LongevityBank from 6.4% to 12.0%, based on a S$5 million post-money valuation.

auto_awesomeAnalysis · GDTC · Life Sciences

This filing details significant personal commitment from the Chairman, Mr. Choo Chee Kong, through two key actions. First, he has offered to acquire up to 200,000 shares via private transactions, signaling strong confidence in the company's equity. Second, he directly invested approximately $250,000 into LongevityBank, a key subsidiary, specifically earmarking funds for an R&D laboratory. This capital injection and commitment to increasing his stake are crucial positive signals, especially given the company's recent disclosure of a going concern warning and financial distress. It provides a much-needed vote of confidence and direct funding for strategic growth initiatives.